R.H. Bluestein & Co’s Sarepta Therapeutics SRPT Stock Holding History

R.H. Bluestein & Co’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-11,000	Closed	-$520K	–	372
2013 Q3	$520K	Buy	+11,000	New	+$424K	0.04%	176

Other funds holding SRPT

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

R.H. Bluestein & Co's SRPT Position: Q4 2013 in Review

R.H. Bluestein & Co sold out of Sarepta Therapeutics (SRPT) in Q4 2013, closing a stake of 11,000 shares — an estimated $520K sold.

R.H. Bluestein & Co first reported a position in SRPT in Q3 2013 and held it in 1 quarter. The position peaked at $520K in Q3 2013. 108 funds tracked by Wall St. Rank hold SRPT as of Q4 2013.

R.H. Bluestein & Co reported no remaining Sarepta Therapeutics position as of Q4 2013 after selling out during the quarter.
R.H. Bluestein & Co sold 11,000 Sarepta Therapeutics shares in Q4 2013, an estimated $520K.
R.H. Bluestein & Co first reported a position in Sarepta Therapeutics in Q3 2013 and held it in 1 quarter.
R.H. Bluestein & Co's Sarepta Therapeutics position peaked at $520K in Q3 2013.
108 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2013.

Based on R.H. Bluestein & Co's 13F filing for Q4 2013, filed 13 Feb 2014.